Study on the cutoff value of exhaled nitric oxide (eNO) for prediction of asthma control levels

Study on the cutoff value of exhaled nitric oxide (eNO) for prediction of asthma control levels - Study on the cutoff value of exhaled nitric oxide (eNO) for prediction of asthma control levels

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000002263

Enrollment

300

Registered

2009-08-01

Start date

2009-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bronchial asthma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Patients(age 20 years or over) diagnosed with bronchial asthma 2)Patients who have been treated by inhaled corticosteroids for the past four weeks or more 3)Patients with written informed consent

Exclusion criteria

Exclusion criteria: Patients with any of the following conditions are excluded: 1) Visited emergency room or were hospitalized due to exacerbation of asthma within 30 days prior to enrollment. 2) Treated with systemic corticosteroids within 30 days prior to enrollment. 3) Acquiring upper/lower respiratory tract infection within 30 days prior to enrollment. 4) Using inhaled corticosteroids solely or with long-acting beta2-agonists (LABAs) at a dosage that exceeds the approved one. 5) Complicating pulmonary diseases as follows: COPD, bronchiectasis, primary pulmonary cancer, connective tissue disease, pulmonary hypertension, and/or cystic disease of the lungs 6) Current smokers

Design outcomes

Primary

Measure	Time frame
1. eNO (exhaled nitric oxide) 2. Asthma control levels (well-controlled / poor-controlled; determined by indices as below) -%FEV1.0 (forced expiratory volume in 1 second percentage) -Score of ACQ(Asthma Control Questionnaire) -Volatility of PEF (peak expiratory flow)	—

Secondary

Measure	Time frame
Frequency in use of short-acting beta2-agonist(SABA)	—

Countries

Japan

Contacts

Public ContactMasamitsu Arai

MC&P Co., Ltd. Medical Sciences Marketing Division

ESCORT@mcp.co.jp06-4716-3315

Outcome results